The global Microbiome Drugs market size was valued at USD 228.4 million in 2022 and is forecast to a readjusted size of USD 1691.5 million by 2029 with a CAGR of 33.1% during review period.
Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.
North America and Europe hold most of market share of microbiome drugs, and North America occupies a share over 77%, on the other hand, Europe takes a share of over 22% in total. Global core microbiome drugs manufacturers include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics etc.
This report is a detailed and comprehensive analysis for global Microbiome Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Symptom. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Microbiome Drugs market size and forecasts, in consumption value ($ Million), 2018-2029
Global Microbiome Drugs market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Microbiome Drugs market size and forecasts, by Type and by Symptom, in consumption value ($ Million), 2018-2029
Global Microbiome Drugs market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Microbiome Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Microbiome Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Interxon
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
AOBiome
Rebiotix
Metabiomics
Ritter Pharmaceuticals
Symberix
OpenBiome
Azitra
Osel
Oral Dosage Form
Enteric Capsules
Gastrointestinal Disorders
Autoimmune Disorders
Diabetes
Cancer
Others
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Microbiome Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Microbiome Drugs, with revenue, gross margin and global market share of Microbiome Drugs from 2018 to 2023.
Chapter 3, the Microbiome Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Microbiome Drugs market forecast, by regions, type and symptom, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Microbiome Drugs.
Chapter 13, to describe Microbiome Drugs research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Microbiome Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Microbiome Drugs by Type
1.3.1 Overview: Global Microbiome Drugs Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Microbiome Drugs Consumption Value Market Share by Type in 2022
1.3.3 Oral Dosage Form
1.3.4 Enteric Capsules
1.4 Global Microbiome Drugs Market by Symptom
1.4.1 Overview: Global Microbiome Drugs Market Size by Symptom: 2018 Versus 2022 Versus 2029
1.4.2 Gastrointestinal Disorders
1.4.3 Autoimmune Disorders
1.4.4 Diabetes
1.4.5 Cancer
1.4.6 Others
1.5 Global Microbiome Drugs Market Size & Forecast
1.6 Global Microbiome Drugs Market Size and Forecast by Region
1.6.1 Global Microbiome Drugs Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Microbiome Drugs Market Size by Region, (2018-2029)
1.6.3 North America Microbiome Drugs Market Size and Prospect (2018-2029)
1.6.4 Europe Microbiome Drugs Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Microbiome Drugs Market Size and Prospect (2018-2029)
1.6.6 South America Microbiome Drugs Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Microbiome Drugs Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Seres Therapeutics
2.1.1 Seres Therapeutics Details
2.1.2 Seres Therapeutics Major Business
2.1.3 Seres Therapeutics Microbiome Drugs Product and Solutions
2.1.4 Seres Therapeutics Microbiome Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Seres Therapeutics Recent Developments and Future Plans
2.2 Assembly Biosciences
2.2.1 Assembly Biosciences Details
2.2.2 Assembly Biosciences Major Business
2.2.3 Assembly Biosciences Microbiome Drugs Product and Solutions
2.2.4 Assembly Biosciences Microbiome Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Assembly Biosciences Recent Developments and Future Plans
2.3 Synthetic Biologics
2.3.1 Synthetic Biologics Details
2.3.2 Synthetic Biologics Major Business
2.3.3 Synthetic Biologics Microbiome Drugs Product and Solutions
2.3.4 Synthetic Biologics Microbiome Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Synthetic Biologics Recent Developments and Future Plans
2.4 Interxon
2.4.1 Interxon Details
2.4.2 Interxon Major Business
2.4.3 Interxon Microbiome Drugs Product and Solutions
2.4.4 Interxon Microbiome Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Interxon Recent Developments and Future Plans
2.5 PureTech
2.5.1 PureTech Details
2.5.2 PureTech Major Business
2.5.3 PureTech Microbiome Drugs Product and Solutions
2.5.4 PureTech Microbiome Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 PureTech Recent Developments and Future Plans
2.6 Synlogic
2.6.1 Synlogic Details
2.6.2 Synlogic Major Business
2.6.3 Synlogic Microbiome Drugs Product and Solutions
2.6.4 Synlogic Microbiome Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Synlogic Recent Developments and Future Plans
2.7 Enterome BioScience
2.7.1 Enterome BioScience Details
2.7.2 Enterome BioScience Major Business
2.7.3 Enterome BioScience Microbiome Drugs Product and Solutions
2.7.4 Enterome BioScience Microbiome Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Enterome BioScience Recent Developments and Future Plans
2.8 4D Pharma
2.8.1 4D Pharma Details
2.8.2 4D Pharma Major Business
2.8.3 4D Pharma Microbiome Drugs Product and Solutions
2.8.4 4D Pharma Microbiome Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 4D Pharma Recent Developments and Future Plans
2.9 Second Genome
2.9.1 Second Genome Details
2.9.2 Second Genome Major Business
2.9.3 Second Genome Microbiome Drugs Product and Solutions
2.9.4 Second Genome Microbiome Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Second Genome Recent Developments and Future Plans
2.10 AOBiome
2.10.1 AOBiome Details
2.10.2 AOBiome Major Business
2.10.3 AOBiome Microbiome Drugs Product and Solutions
2.10.4 AOBiome Microbiome Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 AOBiome Recent Developments and Future Plans
2.11 Rebiotix
2.11.1 Rebiotix Details
2.11.2 Rebiotix Major Business
2.11.3 Rebiotix Microbiome Drugs Product and Solutions
2.11.4 Rebiotix Microbiome Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Rebiotix Recent Developments and Future Plans
2.12 Metabiomics
2.12.1 Metabiomics Details
2.12.2 Metabiomics Major Business
2.12.3 Metabiomics Microbiome Drugs Product and Solutions
2.12.4 Metabiomics Microbiome Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Metabiomics Recent Developments and Future Plans
2.13 Ritter Pharmaceuticals
2.13.1 Ritter Pharmaceuticals Details
2.13.2 Ritter Pharmaceuticals Major Business
2.13.3 Ritter Pharmaceuticals Microbiome Drugs Product and Solutions
2.13.4 Ritter Pharmaceuticals Microbiome Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Ritter Pharmaceuticals Recent Developments and Future Plans
2.14 Symberix
2.14.1 Symberix Details
2.14.2 Symberix Major Business
2.14.3 Symberix Microbiome Drugs Product and Solutions
2.14.4 Symberix Microbiome Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Symberix Recent Developments and Future Plans
2.15 OpenBiome
2.15.1 OpenBiome Details
2.15.2 OpenBiome Major Business
2.15.3 OpenBiome Microbiome Drugs Product and Solutions
2.15.4 OpenBiome Microbiome Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 OpenBiome Recent Developments and Future Plans
2.16 Azitra
2.16.1 Azitra Details
2.16.2 Azitra Major Business
2.16.3 Azitra Microbiome Drugs Product and Solutions
2.16.4 Azitra Microbiome Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Azitra Recent Developments and Future Plans
2.17 Osel
2.17.1 Osel Details
2.17.2 Osel Major Business
2.17.3 Osel Microbiome Drugs Product and Solutions
2.17.4 Osel Microbiome Drugs Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Osel Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Microbiome Drugs Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Microbiome Drugs by Company Revenue
3.2.2 Top 3 Microbiome Drugs Players Market Share in 2022
3.2.3 Top 6 Microbiome Drugs Players Market Share in 2022
3.3 Microbiome Drugs Market: Overall Company Footprint Analysis
3.3.1 Microbiome Drugs Market: Region Footprint
3.3.2 Microbiome Drugs Market: Company Product Type Footprint
3.3.3 Microbiome Drugs Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Microbiome Drugs Consumption Value and Market Share by Type (2018-2023)
4.2 Global Microbiome Drugs Market Forecast by Type (2024-2029)
5 Market Size Segment by Symptom
5.1 Global Microbiome Drugs Consumption Value Market Share by Symptom (2018-2023)
5.2 Global Microbiome Drugs Market Forecast by Symptom (2024-2029)
6 North America
6.1 North America Microbiome Drugs Consumption Value by Type (2018-2029)
6.2 North America Microbiome Drugs Consumption Value by Symptom (2018-2029)
6.3 North America Microbiome Drugs Market Size by Country
6.3.1 North America Microbiome Drugs Consumption Value by Country (2018-2029)
6.3.2 United States Microbiome Drugs Market Size and Forecast (2018-2029)
6.3.3 Canada Microbiome Drugs Market Size and Forecast (2018-2029)
6.3.4 Mexico Microbiome Drugs Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Microbiome Drugs Consumption Value by Type (2018-2029)
7.2 Europe Microbiome Drugs Consumption Value by Symptom (2018-2029)
7.3 Europe Microbiome Drugs Market Size by Country
7.3.1 Europe Microbiome Drugs Consumption Value by Country (2018-2029)
7.3.2 Germany Microbiome Drugs Market Size and Forecast (2018-2029)
7.3.3 France Microbiome Drugs Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Microbiome Drugs Market Size and Forecast (2018-2029)
7.3.5 Russia Microbiome Drugs Market Size and Forecast (2018-2029)
7.3.6 Italy Microbiome Drugs Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Microbiome Drugs Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Microbiome Drugs Consumption Value by Symptom (2018-2029)
8.3 Asia-Pacific Microbiome Drugs Market Size by Region
8.3.1 Asia-Pacific Microbiome Drugs Consumption Value by Region (2018-2029)
8.3.2 China Microbiome Drugs Market Size and Forecast (2018-2029)
8.3.3 Japan Microbiome Drugs Market Size and Forecast (2018-2029)
8.3.4 South Korea Microbiome Drugs Market Size and Forecast (2018-2029)
8.3.5 India Microbiome Drugs Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Microbiome Drugs Market Size and Forecast (2018-2029)
8.3.7 Australia Microbiome Drugs Market Size and Forecast (2018-2029)
9 South America
9.1 South America Microbiome Drugs Consumption Value by Type (2018-2029)
9.2 South America Microbiome Drugs Consumption Value by Symptom (2018-2029)
9.3 South America Microbiome Drugs Market Size by Country
9.3.1 South America Microbiome Drugs Consumption Value by Country (2018-2029)
9.3.2 Brazil Microbiome Drugs Market Size and Forecast (2018-2029)
9.3.3 Argentina Microbiome Drugs Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Microbiome Drugs Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Microbiome Drugs Consumption Value by Symptom (2018-2029)
10.3 Middle East & Africa Microbiome Drugs Market Size by Country
10.3.1 Middle East & Africa Microbiome Drugs Consumption Value by Country (2018-2029)
10.3.2 Turkey Microbiome Drugs Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Microbiome Drugs Market Size and Forecast (2018-2029)
10.3.4 UAE Microbiome Drugs Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Microbiome Drugs Market Drivers
11.2 Microbiome Drugs Market Restraints
11.3 Microbiome Drugs Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Microbiome Drugs Industry Chain
12.2 Microbiome Drugs Upstream Analysis
12.3 Microbiome Drugs Midstream Analysis
12.4 Microbiome Drugs Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Microbiome Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Microbiome Drugs Consumption Value by Symptom, (USD Million), 2018 & 2022 & 2029
Table 3. Global Microbiome Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Microbiome Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Seres Therapeutics Company Information, Head Office, and Major Competitors
Table 6. Seres Therapeutics Major Business
Table 7. Seres Therapeutics Microbiome Drugs Product and Solutions
Table 8. Seres Therapeutics Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Seres Therapeutics Recent Developments and Future Plans
Table 10. Assembly Biosciences Company Information, Head Office, and Major Competitors
Table 11. Assembly Biosciences Major Business
Table 12. Assembly Biosciences Microbiome Drugs Product and Solutions
Table 13. Assembly Biosciences Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Assembly Biosciences Recent Developments and Future Plans
Table 15. Synthetic Biologics Company Information, Head Office, and Major Competitors
Table 16. Synthetic Biologics Major Business
Table 17. Synthetic Biologics Microbiome Drugs Product and Solutions
Table 18. Synthetic Biologics Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Synthetic Biologics Recent Developments and Future Plans
Table 20. Interxon Company Information, Head Office, and Major Competitors
Table 21. Interxon Major Business
Table 22. Interxon Microbiome Drugs Product and Solutions
Table 23. Interxon Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Interxon Recent Developments and Future Plans
Table 25. PureTech Company Information, Head Office, and Major Competitors
Table 26. PureTech Major Business
Table 27. PureTech Microbiome Drugs Product and Solutions
Table 28. PureTech Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. PureTech Recent Developments and Future Plans
Table 30. Synlogic Company Information, Head Office, and Major Competitors
Table 31. Synlogic Major Business
Table 32. Synlogic Microbiome Drugs Product and Solutions
Table 33. Synlogic Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Synlogic Recent Developments and Future Plans
Table 35. Enterome BioScience Company Information, Head Office, and Major Competitors
Table 36. Enterome BioScience Major Business
Table 37. Enterome BioScience Microbiome Drugs Product and Solutions
Table 38. Enterome BioScience Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Enterome BioScience Recent Developments and Future Plans
Table 40. 4D Pharma Company Information, Head Office, and Major Competitors
Table 41. 4D Pharma Major Business
Table 42. 4D Pharma Microbiome Drugs Product and Solutions
Table 43. 4D Pharma Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. 4D Pharma Recent Developments and Future Plans
Table 45. Second Genome Company Information, Head Office, and Major Competitors
Table 46. Second Genome Major Business
Table 47. Second Genome Microbiome Drugs Product and Solutions
Table 48. Second Genome Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Second Genome Recent Developments and Future Plans
Table 50. AOBiome Company Information, Head Office, and Major Competitors
Table 51. AOBiome Major Business
Table 52. AOBiome Microbiome Drugs Product and Solutions
Table 53. AOBiome Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. AOBiome Recent Developments and Future Plans
Table 55. Rebiotix Company Information, Head Office, and Major Competitors
Table 56. Rebiotix Major Business
Table 57. Rebiotix Microbiome Drugs Product and Solutions
Table 58. Rebiotix Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Rebiotix Recent Developments and Future Plans
Table 60. Metabiomics Company Information, Head Office, and Major Competitors
Table 61. Metabiomics Major Business
Table 62. Metabiomics Microbiome Drugs Product and Solutions
Table 63. Metabiomics Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Metabiomics Recent Developments and Future Plans
Table 65. Ritter Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 66. Ritter Pharmaceuticals Major Business
Table 67. Ritter Pharmaceuticals Microbiome Drugs Product and Solutions
Table 68. Ritter Pharmaceuticals Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Ritter Pharmaceuticals Recent Developments and Future Plans
Table 70. Symberix Company Information, Head Office, and Major Competitors
Table 71. Symberix Major Business
Table 72. Symberix Microbiome Drugs Product and Solutions
Table 73. Symberix Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Symberix Recent Developments and Future Plans
Table 75. OpenBiome Company Information, Head Office, and Major Competitors
Table 76. OpenBiome Major Business
Table 77. OpenBiome Microbiome Drugs Product and Solutions
Table 78. OpenBiome Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. OpenBiome Recent Developments and Future Plans
Table 80. Azitra Company Information, Head Office, and Major Competitors
Table 81. Azitra Major Business
Table 82. Azitra Microbiome Drugs Product and Solutions
Table 83. Azitra Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 84. Azitra Recent Developments and Future Plans
Table 85. Osel Company Information, Head Office, and Major Competitors
Table 86. Osel Major Business
Table 87. Osel Microbiome Drugs Product and Solutions
Table 88. Osel Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Osel Recent Developments and Future Plans
Table 90. Global Microbiome Drugs Revenue (USD Million) by Players (2018-2023)
Table 91. Global Microbiome Drugs Revenue Share by Players (2018-2023)
Table 92. Breakdown of Microbiome Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
Table 93. Market Position of Players in Microbiome Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 94. Head Office of Key Microbiome Drugs Players
Table 95. Microbiome Drugs Market: Company Product Type Footprint
Table 96. Microbiome Drugs Market: Company Product Application Footprint
Table 97. Microbiome Drugs New Market Entrants and Barriers to Market Entry
Table 98. Microbiome Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 99. Global Microbiome Drugs Consumption Value (USD Million) by Type (2018-2023)
Table 100. Global Microbiome Drugs Consumption Value Share by Type (2018-2023)
Table 101. Global Microbiome Drugs Consumption Value Forecast by Type (2024-2029)
Table 102. Global Microbiome Drugs Consumption Value by Symptom (2018-2023)
Table 103. Global Microbiome Drugs Consumption Value Forecast by Symptom (2024-2029)
Table 104. North America Microbiome Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 105. North America Microbiome Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 106. North America Microbiome Drugs Consumption Value by Symptom (2018-2023) & (USD Million)
Table 107. North America Microbiome Drugs Consumption Value by Symptom (2024-2029) & (USD Million)
Table 108. North America Microbiome Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 109. North America Microbiome Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 110. Europe Microbiome Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 111. Europe Microbiome Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 112. Europe Microbiome Drugs Consumption Value by Symptom (2018-2023) & (USD Million)
Table 113. Europe Microbiome Drugs Consumption Value by Symptom (2024-2029) & (USD Million)
Table 114. Europe Microbiome Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 115. Europe Microbiome Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 116. Asia-Pacific Microbiome Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 117. Asia-Pacific Microbiome Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 118. Asia-Pacific Microbiome Drugs Consumption Value by Symptom (2018-2023) & (USD Million)
Table 119. Asia-Pacific Microbiome Drugs Consumption Value by Symptom (2024-2029) & (USD Million)
Table 120. Asia-Pacific Microbiome Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 121. Asia-Pacific Microbiome Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 122. South America Microbiome Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 123. South America Microbiome Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 124. South America Microbiome Drugs Consumption Value by Symptom (2018-2023) & (USD Million)
Table 125. South America Microbiome Drugs Consumption Value by Symptom (2024-2029) & (USD Million)
Table 126. South America Microbiome Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 127. South America Microbiome Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 128. Middle East & Africa Microbiome Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 129. Middle East & Africa Microbiome Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 130. Middle East & Africa Microbiome Drugs Consumption Value by Symptom (2018-2023) & (USD Million)
Table 131. Middle East & Africa Microbiome Drugs Consumption Value by Symptom (2024-2029) & (USD Million)
Table 132. Middle East & Africa Microbiome Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 133. Middle East & Africa Microbiome Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 134. Microbiome Drugs Raw Material
Table 135. Key Suppliers of Microbiome Drugs Raw Materials
List of Figures
Figure 1. Microbiome Drugs Picture
Figure 2. Global Microbiome Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Microbiome Drugs Consumption Value Market Share by Type in 2022
Figure 4. Oral Dosage Form
Figure 5. Enteric Capsules
Figure 6. Global Microbiome Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Microbiome Drugs Consumption Value Market Share by Symptom in 2022
Figure 8. Gastrointestinal Disorders Picture
Figure 9. Autoimmune Disorders Picture
Figure 10. Diabetes Picture
Figure 11. Cancer Picture
Figure 12. Others Picture
Figure 13. Global Microbiome Drugs Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Microbiome Drugs Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Market Microbiome Drugs Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 16. Global Microbiome Drugs Consumption Value Market Share by Region (2018-2029)
Figure 17. Global Microbiome Drugs Consumption Value Market Share by Region in 2022
Figure 18. North America Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 20. Asia-Pacific Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 21. South America Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 22. Middle East and Africa Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 23. Global Microbiome Drugs Revenue Share by Players in 2022
Figure 24. Microbiome Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 25. Global Top 3 Players Microbiome Drugs Market Share in 2022
Figure 26. Global Top 6 Players Microbiome Drugs Market Share in 2022
Figure 27. Global Microbiome Drugs Consumption Value Share by Type (2018-2023)
Figure 28. Global Microbiome Drugs Market Share Forecast by Type (2024-2029)
Figure 29. Global Microbiome Drugs Consumption Value Share by Symptom (2018-2023)
Figure 30. Global Microbiome Drugs Market Share Forecast by Symptom (2024-2029)
Figure 31. North America Microbiome Drugs Consumption Value Market Share by Type (2018-2029)
Figure 32. North America Microbiome Drugs Consumption Value Market Share by Symptom (2018-2029)
Figure 33. North America Microbiome Drugs Consumption Value Market Share by Country (2018-2029)
Figure 34. United States Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 35. Canada Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 36. Mexico Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 37. Europe Microbiome Drugs Consumption Value Market Share by Type (2018-2029)
Figure 38. Europe Microbiome Drugs Consumption Value Market Share by Symptom (2018-2029)
Figure 39. Europe Microbiome Drugs Consumption Value Market Share by Country (2018-2029)
Figure 40. Germany Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 41. France Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 42. United Kingdom Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 43. Russia Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 44. Italy Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 45. Asia-Pacific Microbiome Drugs Consumption Value Market Share by Type (2018-2029)
Figure 46. Asia-Pacific Microbiome Drugs Consumption Value Market Share by Symptom (2018-2029)
Figure 47. Asia-Pacific Microbiome Drugs Consumption Value Market Share by Region (2018-2029)
Figure 48. China Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 49. Japan Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 50. South Korea Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 51. India Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 52. Southeast Asia Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 53. Australia Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 54. South America Microbiome Drugs Consumption Value Market Share by Type (2018-2029)
Figure 55. South America Microbiome Drugs Consumption Value Market Share by Symptom (2018-2029)
Figure 56. South America Microbiome Drugs Consumption Value Market Share by Country (2018-2029)
Figure 57. Brazil Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 58. Argentina Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 59. Middle East and Africa Microbiome Drugs Consumption Value Market Share by Type (2018-2029)
Figure 60. Middle East and Africa Microbiome Drugs Consumption Value Market Share by Symptom (2018-2029)
Figure 61. Middle East and Africa Microbiome Drugs Consumption Value Market Share by Country (2018-2029)
Figure 62. Turkey Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 63. Saudi Arabia Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 64. UAE Microbiome Drugs Consumption Value (2018-2029) & (USD Million)
Figure 65. Microbiome Drugs Market Drivers
Figure 66. Microbiome Drugs Market Restraints
Figure 67. Microbiome Drugs Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of Microbiome Drugs in 2022
Figure 70. Manufacturing Process Analysis of Microbiome Drugs
Figure 71. Microbiome Drugs Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
